# Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

> **NCT00388401** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 510 (—)

## Conditions studied

- Ileus

## Interventions

- **DRUG:** Alvimopan

## Key facts

- **NCT ID:** NCT00388401
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 510 (—)
- **Last updated:** 2015-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388401, "Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00388401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*